Advances in research on potential inhibitors of multiple myeloma

被引：3

作者：

Tang, Guoyuan ^{[1
]}

Huang, Shan ^{[2
,3
]}

Luo, Ji ^{[4
,5
]}

Wu, Yingmiao ^{[4
,5
]}

Zheng, Shuai ^{[4
,5
]}

Tong, Rongsheng ^{[1
,6
]}

Zhong, Ling ^{[4
,5
,7
]}

Shi, Jianyou ^{[1
,6
]}

机构：

[1] Chengdu Univ Tradit Chinese Med, State Key Lab Southwestern Chinese Med Resources, Chengdu 611137, Peoples R China

[2] Univ Elect Sci & Technol China, Sichuan Acad Med Sci, Canc Ctr, Chengdu 610072, Sichuan, Peoples R China

[3] Univ Elect Sci & Technol China, Sichuan Prov Peoples Hosp, Sch Med, Chengdu 610072, Sichuan, Peoples R China

[4] Univ Elect Sci & Technol China, Sichuan Acad Med Sci, Ctr Med Genet, Sichuan Prov Key Lab Human Dis Gene Study, Chengdu 610072, Sichuan, Peoples R China

[5] Univ Elect Sci & Technol China, Sichuan Prov Peoples Hosp, Chengdu 610072, Sichuan, Peoples R China

[6] Univ Elect Sci & Technol China, Sichuan Prov Peoples Hosp, Sch Med, Dept Pharm,Personalized Drug Therapy Key Lab Sichu, Chengdu 610072, Sichuan, Peoples R China

[7] Chinese Acad Sci, Chengdu Inst Biol, Chengdu 610041, Sichuan, Peoples R China

来源：

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY | 2023年 / 262卷

基金：

中国国家自然科学基金; 中国博士后科学基金;

关键词：

Multiple myeloma; Drug resistance; Potential drugs; Structure-activity relationships; UBIQUITIN-PROTEASOME-SYSTEM; TOLL-LIKE RECEPTORS; TARGETED PROTEIN-DEGRADATION; DRUG-RESISTANCE; DEUBIQUITINATING ENZYMES; NEDD8-ACTIVATING ENZYME; CELL-PROLIFERATION; KINASE; SUPPRESSES; ACTIVATION;

D O I：

10.1016/j.ejmech.2023.115875

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Multiple myeloma (MM) is a common hematological malignancy. Although recent clinical applications of immunomodulatory drugs, proteasome inhibitors and CD38-targeting antibodies have significantly improved the outcome of MM patient with increased survival, the incidence of drug resistance and severe treatment-related complications is gradually on the rise. This review article summarizes the characteristics and clinical investigations of several MM drugs in clinical trials, including their structures, mechanisms of action, structure activity relationships, and clinical study progress. Furthermore, the application potentials of the drugs that have not yet entered clinical trials are also reviewed. The review also outlines the future directions of MM drug development.

引用

页数：19

共 50 条

[31] Recent advances in the treatment of multiple myeloma
Yasui, Hiroshi
Hideshima, Teru
Richardson, Paul G.
Anderson, Kenneth C.
CURRENT PHARMACEUTICAL BIOTECHNOLOGY, 2006, 7 (05) : 381 - 393
[32] Advances in biology and treatment of multiple myeloma
Ludwig, H
ANNALS OF ONCOLOGY, 2005, 16 : 106 - 112
[33] Advances in therapeutic approaches for multiple myeloma
Kizaki, Masahiro
Tabayashi, Takayuki
ANNALS OF ONCOLOGY, 2018, 29 : 29 - 29
[34] LYMPHOMA AND MULTIPLE MYELOMA - ADVANCES IN MANAGEMENT
MILLER, SP
NEW YORK STATE JOURNAL OF MEDICINE, 1970, 70 (24) : 2982 - &
[35] Recent advances in the mangement of multiple myeloma
Kumar, Lalit
Vikram, P.
Kochupillai, V.
NATIONAL MEDICAL JOURNAL OF INDIA, 2006, 19 (02): : 80 - 89
[36] ADVANCES IN THE TREATMENT OF MULTIPLE-MYELOMA
LOKHORST, HM
DEKKER, AW
CANCER TREATMENT REVIEWS, 1993, 19 (02) : 113 - 128
[37] Advances in Supportive Care for Multiple Myeloma
Raje, Noopur S.
Yee, Andrew J.
Roodman, G. David
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2014, 12 (04): : 502 - 511
[38] NSD3: Advances in cancer therapeutic potential and inhibitors research
Xiu, Siyu
Chi, Xiaowei
Jia, Zhenyu
Shi, Cheng
Zhang, Xiangyu
Li, Qi
Gao, Tongfei
Zhang, Liangren
Liu, Zhenming
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2023, 256
[39] Advances in myeloma genetics and prospects for pharmacogenomic testing in multiple myeloma
Claudio, JO
Stewart, AK
AMERICAN JOURNAL OF PHARMACOGENOMICS, 2005, 5 (01) : 35 - 43
[40] Proteasome inhibitors in the treatment of multiple myeloma
McBride, Ali
Ryan, Patricia Y.
EXPERT REVIEW OF ANTICANCER THERAPY, 2013, 13 (03) : 339 - 358

← 1 2 3 4 5 →